Johnson & Johnson Sees Unusual Bullish Options Bet Worth $1.48M Targeting $290 by January 2028

By TrendSpider Editor

A single unusual call contract on Johnson & Johnson caught the market's attention Monday, with a trader placing a $1,480,000 premium on JNJ shares reaching $290 by January 2028. The contract stands well out of the money relative to the current price of $253.99, implying a roughly 14% move to the ups

Johnson & Johnson Sees Unusual Bullish Options Bet Worth $1.48M Targeting $290 by January 2028

A single unusual call contract on Johnson & Johnson caught the market's attention Monday, with a trader placing a $1,480,000 premium on JNJ shares reaching $290 by January 2028. The contract stands well out of the money relative to the current price of $253.99, implying a roughly 14% move to the upside from current levels. JNJ shares are trading near the upper half of their 52-week range of $179.84 to $281.07, suggesting the stock has already made a significant run but still has room before testing its yearly high.

Key Drivers of the JNJ Stock Move

• Main Catalyst: A single call contract with a $290 strike expiring January 21, 2028 was flagged as unusual, carrying a total premium of $1,480,000. The contract showed a volume-to-open-interest ratio reflecting 98% OTM positioning, meaning this is a high-conviction directional bet placed with relatively little prior open interest at that strike.
• Bull Case: The size of the premium, $1,480,000 on a single call, signals that at least one large participant believes JNJ can push toward or beyond $290 within the next 15-plus months. That level would represent a new 52-week high above the current peak of $281.07, implying a breakout scenario is being priced into this trade.
• Bear Case: The $290 strike is deeply out of the money relative to the current price of $253.99, meaning the contract requires a substantial move to generate a profit at expiration. With JNJ already down 0.82% on the session and the stock having not yet breached its 52-week high of $281.07, this trade carries meaningful risk of expiring worthless if the stock stalls or pulls back from current levels.

JNJ shares are entering the week with modest selling pressure, slipping 0.82% on Monday. The long-dated nature of the January 2028 expiry gives the position considerable time to play out, which may suggest the trader is positioning around a multi-quarter fundamental thesis rather than a near-term catalyst. Johnson & Johnson continues to navigate its post-Kenvue separation identity as a pure-play pharmaceutical and MedTech company, and any updates around pipeline approvals, litigation resolutions, or capital allocation could serve as meaningful catalysts between now and expiration. The wide 52-week range from $179.84 to $281.07 reflects the stock's volatility over the past year, and a sustained move toward the $290 target would mark a meaningful extension of the current recovery.

JNJ Unusual Options Activity

One unusual options contract was flagged on JNJ today:

• Type: Call | Strike: $290 | Expiry: January 21, 2028 | Volume: 800 | Open Interest: 98% OTM

The total premium tied to this single contract block came in at $1,480,000, making it the sole driver of today's unusual options activity on JNJ. With a call count of zero beyond this flagged contract, the activity is concentrated entirely in this one directional position, lending it additional significance as a potential institutional or high-net-worth trade.

JNJ Seasonality

October has historically been a transitional month for healthcare names, with fourth-quarter positioning often picking up as investors rotate ahead of year-end earnings cycles. A long-dated January 2028 call placed in early October gives the holder exposure through multiple earnings cycles and any potential year-end or new-year momentum.

JNJ Relative Performance

JNJ's current price of $253.99 reflects a stock that has recovered substantially from its 52-week low of $179.84 but remains below its 52-week high of $281.07, leaving approximately 10.7% of upside before the stock sets a new annual peak. Today's 0.82% decline suggests modest underperformance on a session-by-session basis, though the broader context of the options activity indicates longer-term confidence from at least one significant market participant.